CHEMED CORP
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
CHE$544.49+1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidating Statements of Income
| CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||
|---|---|---|---|---|---|---|---|
| UNAUDITED CONSOLIDATING STATEMENTS OF INCOME | |||||||
| FOR THE YEAR ENDED DECEMBER 31, 2025 | |||||||
| (in thousands)(unaudited) | |||||||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| Service revenues and sales | $1,630,101 | $899,877 | $ | - | $2,529,978 | ||
| Cost of services provided and goods sold | 1,257,704 | 449,090 | - | 1,706,794 | |||
| Selling, general and administrative expenses | 100,675 | 247,047 | 69,466 | 417,188 | |||
| Depreciation | 21,308 | 33,200 | 49 | 54,557 | |||
| Amortization | 104 | 10,180 | - | 10,284 | |||
| Other operating expense/(income) | 3,375 | (466) | - | 2,909 | |||
| Total costs and expenses | 1,383,166 | 739,051 | 69,515 | 2,191,732 | |||
| Income/(loss) from operations | 246,935 | 160,826 | (69,515) | 338,246 | |||
| Interest expense | (185) | (611) | (954) | (1,750) | |||
| Intercompany interest income/(expense) | 22,455 | 16,245 | (38,700) | - | |||
| Other income—net | 327 | 70 | 18,885 | 19,282 | |||
| Income/(loss) before income taxes (a) | 269,532 | 176,530 | (90,284) | 355,778 | |||
| Income taxes | (65,523) | (41,037) | 16,020 | (90,540) | |||
| Net income/(loss) (a) | $204,009 | $135,493 | $(74,264) | $265,238 | |||
| (a) The following amounts are included in income from continuing operations (in thousands): | |||||||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| Pretax benefit/(cost): | |||||||
| Stock option expense | $ | - | $ | - | $(32,671) | $(32,671) | |
| Amortization of reacquired franchise agreements | - | (9,408) | - | (9,408) | |||
| Long-term incentive compensation | - | - | (5,625) | (5,625) | |||
| Legal settlements | (3,071) | - | - | (3,071) | |||
| Other | (500) | (530) | (2,690) | (3,720) | |||
| Total | $(3,571) | $(9,938) | $(40,986) | $(54,495) | |||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| After-tax benefit/(cost): | |||||||
| Stock option expense | $ | - | $ | - | $(27,659) | $(27,659) | |
| Amortization of reacquired franchise agreements | - | (7,216) | - | (7,216) | |||
| Long-term incentive compensation | - | - | (4,972) | (4,972) | |||
| Legal settlements | (2,325) | - | - | (2,325) | |||
| Other | (378) | (406) | (2,690) | (3,474) | |||
| Excess tax expense on stock compensation | - | - | (696) | (696) | |||
| Total | $(2,703) | $(7,622) | $(36,017) | $(46,342) | |||
| CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||
|---|---|---|---|---|---|---|---|
| UNAUDITED CONSOLIDATING STATEMENTS OF INCOME | |||||||
| FOR THE YEAR ENDED DECEMBER 31, 2024 | |||||||
| (in thousands)(unaudited) | |||||||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| Service revenues and sales | $1,530,978 | $900,309 | $ | - | $2,431,287 | ||
| Cost of services provided and goods sold | 1,146,803 | 430,136 | - | 1,576,939 | |||
| Selling, general and administrative expenses | 99,564 | 232,852 | 91,944 | 424,360 | |||
| Depreciation | 20,362 | 32,452 | 50 | 52,864 | |||
| Amortization | 105 | 10,080 | - | 10,185 | |||
| Other operating expenses | 178 | 268 | - | 446 | |||
| Total costs and expenses | 1,267,012 | 705,788 | 91,994 | 2,064,794 | |||
| Income/(loss) from operations | 263,966 | 194,521 | (91,994) | 366,493 | |||
| Interest expense | (171) | (431) | (1,178) | (1,780) | |||
| Intercompany interest income/(expense) | 20,211 | 14,397 | (34,608) | - | |||
| Other income—net | 227 | 69 | 34,456 | 34,752 | |||
| Income/(loss) before income taxes (a) | 284,233 | 208,556 | (93,324) | 399,465 | |||
| Income taxes | (67,414) | (48,510) | 18,458 | (97,466) | |||
| Net income/(loss) (a) | $216,819 | $160,046 | $(74,866) | $301,999 | |||
| (a) The following amounts are included in income from continuing operations (in thousands): | |||||||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| Pretax benefit/(cost): | |||||||
| Stock option expense | $ | - | $ | - | $(32,033) | $(32,033) | |
| Long-term incentive compensation | - | - | (20,152) | (20,152) | |||
| Amortization of reacquired franchise agreements | - | (9,408) | - | (9,408) | |||
| Acquisition expense | (1,099) | (34) | - | (1,133) | |||
| Total | $(1,099) | $(9,442) | $(52,185) | $(62,726) | |||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| After-tax benefit/(cost): | |||||||
| Stock option expense | $ | - | $ | - | $(27,053) | $(27,053) | |
| Long-term incentive compensation | - | - | (18,504) | (18,504) | |||
| Amortization of reacquired franchise agreements | - | (7,216) | - | (7,216) | |||
| Acquisition expense | (832) | (26) | - | (858) | |||
| Excess tax benefits on stock compensation | - | - | 4,442 | 4,442 | |||
| Total | $(832) | $(7,242) | $(41,115) | $(49,189) | |||
| CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||
|---|---|---|---|---|---|---|---|
| UNAUDITED CONSOLIDATING STATEMENTS OF INCOME | |||||||
| FOR THE YEAR ENDED DECEMBER 31, 2023 | |||||||
| (in thousands)(unaudited) | |||||||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| Service revenues and sales | $1,315,065 | $949,352 | $ | - | $2,264,417 | ||
| Cost of services provided and goods sold | 1,017,623 | 447,979 | - | 1,465,602 | |||
| Selling, general and administrative expenses | 93,296 | 231,587 | 70,237 | 395,120 | |||
| Depreciation | 19,959 | 30,790 | 53 | 50,802 | |||
| Amortization | 104 | 9,959 | - | 10,063 | |||
| Other operating expenses/(income) | (12) | 2,273 | - | 2,261 | |||
| Total costs and expenses | 1,130,970 | 722,588 | 70,290 | 1,923,848 | |||
| Income/(loss) from operations | 184,095 | 226,764 | (70,290) | 340,569 | |||
| Interest expense | (180) | (442) | (2,486) | (3,108) | |||
| Intercompany interest income/(expense) | 19,400 | 11,918 | (31,318) | - | |||
| Other income—net | 1,309 | 126 | 11,471 | 12,906 | |||
| Income/(loss) before income taxes (a) | 204,624 | 238,366 | (92,623) | 350,367 | |||
| Income taxes | (46,115) | (50,125) | 18,382 | (77,858) | |||
| Net income/(loss) (a) | $158,509 | $188,241 | $(74,241) | $272,509 | |||
| (a) The following amounts are included in income from continuing operations (in thousands): | |||||||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| Pretax benefit/(cost): | |||||||
| Stock option expense | $ | - | $ | - | $(30,082) | $(30,082) | |
| Long-term incentive compensation | - | - | (11,689) | (11,689) | |||
| Amortization of reacquired franchise agreements | - | (9,408) | - | (9,408) | |||
| Legal settlements | - | (2,056) | - | (2,056) | |||
| Total | $ | - | $(11,464) | $(41,771) | $(53,235) | ||
| Roto- · Chemed | |||||||
| VITAS · Rooter · Corporate · Consolidated | |||||||
| After-tax benefit/(cost): | |||||||
| Stock option expense | $ | - | $ | - | $(25,405) | $(25,405) | |
| Long-term incentive compensation | - | - | (10,379) | (10,379) | |||
| Amortization of reacquired franchise agreements | - | (7,216) | - | (7,216) | |||
| Impact of deferred rate tax change | 1,772 | 3,559 | (1,090) | 4,241 | |||
| Legal settlements | - | (1,577) | - | (1,577) | |||
| Excess tax benefits on stock compensation | - | - | 4,330 | 4,330 | |||
| Total | $1,772 | $(5,234) | $(32,544) | $(36,006) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.